Vaccine targeting to mucosal lymphoid tissues promotes humoral immunity in the gastrointestinal tract

1Citations
Citations of this article
9Readers
Mendeley users who have this article in their library.

Abstract

Viruses, bacteria, and parasites frequently cause infections in the gastrointestinal tract, but traditional vaccination strategies typically elicit little or no mucosal antibody responses. Here, we report a strategy to effectively concentrate immunogens and adjuvants in gut-draining lymph nodes (LNs) to induce gut-associated mucosal immunity. We prepared nanoemulsions (NEs) based on biodegradable oils commonly used as vaccine adjuvants, which encapsulated a potent Toll-like receptor agonist and displayed antigen conjugated to their surface. Following intraperitoneal administration, these NEs accumulated in gut-draining mesenteric LNs, priming strong germinal center responses and promoting B cell class switching to immunoglobulin A (IgA). Optimized NEs elicited 10- to 1000-fold higher antigen-specific IgG and IgA titers in the serum and feces, respectively, compared to free antigen mixed with NE, and strong neutralizing antibody titers against severe acute respiratory syndrome coronavirus 2. Thus, robust gut humoral immunity can be elicited by exploiting the unique lymphatic collection pathways of the gut with a lymph-targeting vaccine formulation.

Cite

CITATION STYLE

APA

Kocabiyik, O., Amlashi, P., Vo, A. L., Suh, H., Rodriguez-Aponte, S. A., Dalvie, N. C., … Irvine, D. J. (2024). Vaccine targeting to mucosal lymphoid tissues promotes humoral immunity in the gastrointestinal tract. Science Advances, 10(22). https://doi.org/10.1126/sciadv.adn7786

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free